A statistical analysis of the initial biodistribution of 153Sm-EDTMP in a canine

Galiano, Eduardo; Stradiotto, Marco

doi:10.1016/j.apradiso.2005.01.006

Cited by 4 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The assumptions for the calculation were as follows: all b-energy, all Auger electron energy, and 5% of g-energy would be absorbed within 0.20 cm of the disintegration point; the energy deposition from 176m Lu and 177m Lu would be less than 1% of the total; the average b-energy is 34% of the maximum dose (D max ); uptake would be approximately 16% of the dose injected into the skeleton (6,7); the density of bone is 1.7 times greater than that of tissue; the skeletal mass is approximately 9% of the total dog body mass; and the radiation dose would be evenly distributed in bone. An uptake of 16% is very conservative compared with uptake in a rat model and relative to reported 153 Sm-EDTMP uptake in humans and dogs (9,15,16).…”

Section: Dosimetrymentioning

confidence: 83%

“…Aminobisphosphonates, similar in structure to EDTMP, were administered to normal dogs and resulted in a decrease in measured bone ALP activity (18). Furthermore, significant liver uptake was identified in an imaging biodistribution study of a single normal dog (15). Given the statistically significant difference in ALP levels between dogs receiving 153 Sm-EDTMP and those receiving 177 Lu-DOTMP, it is possible that the level of elimination of 177 Lu-DOTMP by the liver was lower.…”

Section: Dogs Receiving 177mentioning

confidence: 99%

“…The skeletal dose reported here was intended to be very conservative to establish a minimum safe dose for veterinary clinical studies. The skeletal uptake of 16% is very conservative, and the uptake may, in fact, be much higher, delivering a higher total skeletal dose (9,15,16). Nevertheless, this dose was very well tolerated by the dogs in the present experiment.…”

Section: Dogs Receiving 177mentioning

confidence: 99%

See 2 more Smart Citations

Comparison of Systemic Toxicities of 177Lu-DOTMP and 153Sm-EDTMP Administered Intravenously at Equivalent Skeletal Doses to Normal Dogs

Bryan¹,

Bommarito²,

Kim³

et al. 2009

Journal of Nuclear Medicine Technology

View full text Add to dashboard Cite

show abstract

Section: Dosimetrymentioning

confidence: 83%

Section: Dogs Receiving 177mentioning

confidence: 99%

Section: Dogs Receiving 177mentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Systemic Toxicities of 177Lu-DOTMP and 153Sm-EDTMP Administered Intravenously at Equivalent Skeletal Doses to Normal Dogs

Bryan¹,

Bommarito²,

Kim³

et al. 2009

Journal of Nuclear Medicine Technology

View full text Add to dashboard Cite

show abstract

“…Although biodistribution and dosimetry studies of 153 Sm-EDTMP have been conducted on animals, [22][23][24] the existing human data are almost exclusively in patients with bone metastases of epithelial cancers [25][26][27][28][29][30][31] or for bone marrow transplant 32 or toxicity studies 33 where the focus is not on dosimetry, although with a few notable exceptions. 17,34 In this study, the authors present the methods and results of a retrospective planar imaging-based tumor dosimetry analysis in 14 metastatic osteosarcoma patients treated with 153 Sm-EDTMP, which complements previously published clinical results.…”

Section: Introductionmentioning

confidence: 99%

Strengths and Weaknesses of a Planar Whole-Body Method of ¹⁵³Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry

Plyku

Loeb

Prideaux

et al. 2015

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Purpose: Dosimetric accuracy depends directly upon the accuracy of the activity measurements in tumors and organs. The authors present the methods and results of a retrospective tumor dosimetry analysis in 14 patients with a total of 28 tumors treated with high activities of 153 Sm-EDTMP) for therapy of metastatic osteosarcoma using planar images and compare the results with three-dimensional dosimetry. Materials and Methods: Analysis of phantom data provided a complete set of parameters for dosimetric calculations, including buildup factor, attenuation coefficient, and camera dead-time compensation. The latter was obtained using a previously developed methodology that accounts for the relative motion of the camera and patient during whole-body (WB) imaging. Tumor activity values calculated from the anterior and posterior views of WB planar images of patients treated with 153 Sm-EDTMP for pediatric osteosarcoma were compared with the geometric mean value. The mean activities were integrated over time and tumor-absorbed doses were calculated using the software package OLINDA/EXM. Results: The authors found that it was necessary to employ the dead-time correction algorithm to prevent measured tumor activity half-lives from often exceeding the physical decay half-life of 153 Sm. Measured halflives so long are unquestionably in error. Tumor-absorbed doses varied between 0.0022 and 0.27 cGy/MBq with an average of 0.065 cGy/MBq; however, a comparison with absorbed dose values derived from a threedimensional analysis for the same tumors showed no correlation; moreover, the ratio of three-dimensional absorbed dose value to planar absorbed dose value was 2.19. From the anterior and posterior activity comparisons, the order of clinical uncertainty for activity and dose calculations from WB planar images, with the present methodology, is hypothesized to be about 70%. Conclusion: The dosimetric results from clinical patient data indicate that absolute planar dosimetry is unreliable and dosimetry using three-dimensional imaging is preferable, particularly for tumors, except perhaps for the most sophisticated planar methods. The relative activity and patient kinetics derived from planar imaging show a greater level of reliability than the dosimetry.

show abstract

Controlled size and morphology of EDTMP-doped hydroxyapatite nanoparticles as model for 153Samarium-EDTMP doping

Han

Loo

Phung

et al. 2008

J Mater Sci: Mater Med

View full text Add to dashboard Cite

Hydroxyapatite (HA) nanoparticles have been studied as nano-sized carriers for the delivery of therapeutic agents. One important consideration for these carriers to be used effectively is their bio-distribution in vivo, of which particle size has a significant effect. In this work, HA nanoparticles doped with Ethylene-diamine-tetramethylene-phosphonate (EDTMP) were synthesized via co-precipitation as a model for HA doped with (153)Samarium ((153)Sm) EDTMP. EDTMP has high affinity for radioactive (153)Sm isotopes that can emit both gamma and beta radiation. The effects of synthesis temperature, amount of dopant and hydrothermal treatment on the size of HA-EDTMP nanoparticles were therefore studied. The results showed that the EDTMP ligand was successfully incorporated in the nanoparticles without changing the crystal structure as shown from X-ray diffractometer (XRD) analysis. From the Field Emission Scanning Electron Microscopy (FESEM) and Transmission Electron Microscopy (TEM) micrographs, it was observed that shorter rod-like nanoparticles, obtained at low synthesis temperatures, became elongated needle-like nanoparticles with increasing temperature. Increasing dopant amount by five fold increases particle size slightly, while a two fold increase in dopant amount has no significant effect. Hydrothermal treatment increases particle crystallinity and results in smooth elongated rod-like structures. The size of HA nanoparticles doped with EDTMP can therefore be manipulated by controlling synthesis temperature and through hydrothermal treatment.

show abstract

A statistical analysis of the initial biodistribution of 153Sm-EDTMP in a canine

Cited by 4 publications

References 5 publications

Comparison of Systemic Toxicities of 177Lu-DOTMP and 153Sm-EDTMP Administered Intravenously at Equivalent Skeletal Doses to Normal Dogs

Comparison of Systemic Toxicities of 177Lu-DOTMP and 153Sm-EDTMP Administered Intravenously at Equivalent Skeletal Doses to Normal Dogs

Strengths and Weaknesses of a Planar Whole-Body Method of ¹⁵³Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry

Controlled size and morphology of EDTMP-doped hydroxyapatite nanoparticles as model for 153Samarium-EDTMP doping

Contact Info

Product

Resources

About

A statistical analysis of the initial biodistribution of 153Sm-EDTMP in a canine

Cited by 4 publications

References 5 publications

Comparison of Systemic Toxicities of 177Lu-DOTMP and 153Sm-EDTMP Administered Intravenously at Equivalent Skeletal Doses to Normal Dogs

Comparison of Systemic Toxicities of 177Lu-DOTMP and 153Sm-EDTMP Administered Intravenously at Equivalent Skeletal Doses to Normal Dogs

Strengths and Weaknesses of a Planar Whole-Body Method of 153Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry

Controlled size and morphology of EDTMP-doped hydroxyapatite nanoparticles as model for 153Samarium-EDTMP doping

Contact Info

Product

Resources

About

Strengths and Weaknesses of a Planar Whole-Body Method of ¹⁵³Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry